STAT | May 19, 2021
Read the PublicationThe Biden administration’s announcement to support an intellectual property (IP) waiver for Covid-19 vaccines was a monumental step toward improving the access to them in low- and middle-income countries. But without further action, it will be little more than a symbol.
The waiver allows companies to produce Covid-19 vaccines without fear of being sued by the entity that holds the IP for the technology.